Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats
Open Access
- 20 January 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 154
Abstract
It is estimated that in patients taking antipsychotic drugs (APDs), metabolic syndrome occurs 2–3 times more often than in the general population. It manifests itself in abdominal obesity, elevated glucose concentration, and dyslipidemia. Despite the high prevalence of this disorder, only a small percentage of patients receive appropriate and effective treatment, and none of the available methods for preventing or treating APD-induced metabolic side effects is satisfactory. A promising supplement to antipsychotic therapy appears to be ligands of the serotonin 6 (5-HT6) receptor. The present study aimed to examine the chronic effects of the selected APDs (haloperidol, risperidone, olanzapine), administered alone and in combination with a selective 5-HT6 agonist (WAY-181187) or antagonist (SB-742457), on weight gain, food intake, serum lipid profile, glucose level, and a spectrum of hormones derived from adipose (leptin, adiponectin) and gastrointestinal (insulin, ghrelin) tissue in rats. SB-742457 inhibited increased weight gain and alleviated hyperglycemia induced by APDs more strongly than did WAY-181187, but also intensified dyslipidemia. WAY-181187 tended to improve the lipid profile, but increased the glucose level. The greatest benefits were obtained when WAY-181187 or SB-742457 were co-administered with haloperidol. It is difficult to assess whether the modification of the serum levels of insulin, leptin, ghrelin, and adiponectin depended on the treatment applied or other drug-independent factors; therefore, further research is needed.Keywords
Funding Information
- Narodowe Centrum Nauki (UMO-2015/19/B/NZ7/00227)
This publication has 55 references indexed in Scilit:
- Sensitivity of the female rat to olanzapine-induced weight gain—Far from the clinic?Schizophrenia Research, 2010
- Risperidone Treatment Increases CB1 Receptor Binding in Rat BrainNeuroendocrinology, 2009
- GABAA receptors in nucleus accumbens shell mediate the hyperphagia and weight gain following haloperidol treatment in ratsLife Sciences, 2009
- Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinSchizophrenia Research, 2008
- Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disordersPharmacology & Therapeutics, 2008
- Discovery of N1-(6-Chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a Potent, Selective, and Orally Active 5-HT6Receptor AgonistJournal of Medicinal Chemistry, 2007
- Chronic 5‐HT 6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese ratsBritish Journal of Pharmacology, 2006
- cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effectsThe Pharmacogenomics Journal, 2005
- Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular ModelingMolecular Pharmacology, 2003
- Impaired Multimerization of Human Adiponectin Mutants Associated with DiabetesJournal of Biological Chemistry, 2003